查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1945816

基因组医学市场－全球产业规模、份额、趋势、机会及预测（按应用、最终用户、地区和竞争格局划分，2021-2031年）

Genomic Medicine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球基因组医学市场预计将从 2025 年的 396.1 亿美元成长到 2031 年的 702.1 亿美元，复合年增长率达到 10.01%。

基因组医学利用个体的基因组资讯来指导临床决策，并透过精准诊断和个人化治疗策略实现客製化医疗保健。基因数据可及性的提高是推动这一市场成长的根本因素，这主要得益于DNA定序成本的大幅下降，以及需要标靶治疗的慢性病和癌症在全球日益普遍。此外，各国政府对大规模人群基因组研究倡议的巨额投资也成为推动该产业发展的关键催化剂。正如个人化医疗联盟所指出的，美国食品药物管理局（FDA）预计将在2024年核准18种新型个人化药物，凸显了该领域对治疗研发和患者照护日益增长的影响力。

市场概览
预测期 2027-2031
市场规模：2025年 396.1亿美元
市场规模：2031年 702.1亿美元
复合年增长率：2026-2031年 10.01%
成长最快的细分市场 肿瘤学
最大的市场 北美洲

然而，基因组检测及相关服务的报销体系往往复杂且不一致，因此市场面临许多挑战。进行全面基因组检测的高昂成本以及支付方覆盖范围的不确定性，构成了巨大的财务障碍，阻碍了医疗机构的采用，并限制了患者的就医途径。这给支付方在製定清晰的效用模型方面带来了挑战，可能导致商业化进程延误，并阻碍基因组医学解决方案在常规医疗实践中的广泛应用。

市场驱动因素

人工智慧 (AI) 与生物资讯学在基因组数据分析中的融合，正透过高效解读庞大而复杂的生物数据集，迅速改变这一领域。随着基因组数据的生成量超出人类的分析能力，机器学习演算法对于识别疾病生物标记和加速治疗方法研发至关重要。这种技术融合正吸引大量投资。例如，成立于 2024 年 4 月的 Xaira Therapeutics 已投入超过 10 亿美元，用于建立一个旨在革新药物发现和个人化医疗的 AI 驱动平台。这笔巨额资金筹措的流入凸显了业界向以 AI 为中心的基因组解决方案的转变，这些解决方案能够预测患者反应并优化临床试验，从而缩短研发週期并提高医疗干预的准确性。

同时，政府的大力资助和大规模人群基因组学计划为检验不同人群的基因组学发现奠定了必要的基础。国家生物银行计画正在扩大规模，以确保基因资料库能够反映全球多样性，而这对于精准医疗的普遍应用至关重要。英国就是这种规模的典型例证。 2024年10月，英国研究与创新署（UKRI）报告称，其「我们的未来健康」（Our Future Health）计画——全球规模最大的健康研究纵向队列研究——已达到历史性的里程碑，招募了超过一百万名志工。营运成本的快速下降进一步推动了这一规模的扩大。例如，Ultima Genomics公司于2024年2月商业性的UG 100定序平台，能够以突破性的100美元价格完成人类基因基因测序。

市场挑战

复杂且时常不一致的医保报销环境对全球基因组医学市场的成长构成重大障碍。保险公司和公共医疗机构往往缺乏统一的框架来评估先进基因组检测的临床和效用，导致健保报销决定难以预测，拒赔现像也屡见不鲜。这种不稳定性为医疗服务提供者带来巨大的财务风险，如果无法保证获得报销，他们便会犹豫是否实施全面的检测通讯协定。因此，经济负担往往转嫁到患者身上，限制了患者获得个人化治疗的机会，并阻碍了基因组医学从小众应用领域向标准临床实践的转变。

这种碎片化的保险覆盖环境直接阻碍了市场扩张，造成了地理上的可及性差异。根据美国癌症协会癌症行动网络统计，截至2024年，美国仅有16个州立法强制要求州监管的保险计划涵盖全面的生物标记检测。这项数据凸显了目前基因组分析的可近性取决于患者居住而非医疗必要性，也暴露出缺乏统一的报销机制。这种监管体系的碎片化使得诊断开发商的商业化策略复杂化，限制了检测的普及，减缓了基因组医学领域的收入成长。

市场趋势

CRISPR 和新一代基因编辑疗法的临床应用正推动市场从症状治疗转向根治性治疗。这一趋势包括编辑技术的进步、监管核准和商业性可行性检验，同时研发人员也在不断改进递送机制，以扩大目标患者群体，使其不再局限于罕见疾病。其财务影响显而易见：CRISPR Therapeutics 于 2024 年 2 月发布的 2023 年第四季及全年财务报告累计，其首个已通过核准的CRISPR 疗法的里程碑付款带来了 8,930 万美元的净收入。这项盈利表明，基因编辑正在发展成为一种永续的收入来源。

液态生物检体作为一种非侵入性癌症检测方法，其广泛应用正在重新定义诊断标准，透过血液检测即可实现疾病的早期发现。此方法最大限度地降低了组织切片检查相关的操作风险，同时能够即时监测肿瘤进展。不断累积的临床疗效数据促使市场对这些检测方法在治疗选择中的应用日益广泛。这种应用也体现在财务业绩上，Guardant Health在2024年8月发布的「2024财年第二季财务业绩」中报告称，其营收为1.772亿美元，同比增长29%。这种增长也印证了循环肿瘤DNA分析在常规肿瘤学中日益重要的作用。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因组医学市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依应用领域（肿瘤学、心臟病学、内分泌学、罕见遗传疾病等）
    • 依最终使用者（医院/诊所、学术/研究机构、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美基因组医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲基因组医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区基因组医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲基因组医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲基因组医学市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球基因组医学市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 7805

The Global Genomic Medicine Market is projected to expand from USD 39.61 Billion in 2025 to USD 70.21 Billion by 2031, achieving a CAGR of 10.01%. Genomic medicine involves leveraging an individual's genomic information to guide clinical decision-making, allowing for the customization of healthcare through precise diagnosis and tailored therapeutic strategies. This market growth is fundamentally supported by the drastic reduction in DNA sequencing costs, which has enhanced the accessibility of genetic data, alongside the increasing global prevalence of chronic diseases and cancers requiring targeted interventions. Additionally, significant government investment in population-scale genomics initiatives acts as a critical catalyst for industry progress. As noted by the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 18 new personalized medicines in 2024, highlighting the sector's expanding influence on therapeutic development and patient care.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 39.61 Billion
Market Size 2031USD 70.21 Billion
CAGR 2026-203110.01%
Fastest Growing SegmentOncology
Largest MarketNorth America

However, the market faces a major obstacle due to the complex and often inconsistent reimbursement landscape for genomic testing and related services. The high costs involved in implementing comprehensive genomic assays, combined with uncertain coverage policies from payers, create substantial financial barriers that deter provider adoption and limit patient access. This difficulty in defining clear economic utility models for insurers risks slowing the commercialization process and hindering the broader integration of genomic medicine solutions into routine medical practice.

Market Driver

The integration of Artificial Intelligence and Bioinformatics for genomic data analysis is rapidly transforming the sector by enabling the efficient interpretation of massive and complex biological datasets. With genomic data generation exceeding human analytical capabilities, machine learning algorithms have become essential for identifying disease biomarkers and accelerating therapeutic development. This technological convergence is attracting significant investment; for example, Xaira Therapeutics launched in April 2024 with over $1 billion in committed capital to build an AI-driven platform aimed at revolutionizing drug discovery and personalized medicine. Such substantial capital inflows underscore the industry's shift toward AI-centric genomic solutions that can predict patient responses and optimize clinical trials, thereby shortening development timelines and improving the precision of medical interventions.

Simultaneously, robust government funding and large-scale population genomics initiatives are providing the necessary infrastructure to validate these genomic insights across diverse groups. National biobanking projects are scaling up to ensure genetic databases reflect global diversity, which is critical for the universal applicability of precision medicine. A prime example of this scale is in the UK, where UK Research and Innovation reported in October 2024 that the Our Future Health programme reached a historic milestone by recruiting over 1 million volunteers, establishing itself as the world's largest longitudinal cohort study for health research. This expansion is further facilitated by plummeting operational costs, demonstrated when Ultima Genomics commercially launched its UG 100 sequencing platform in February 2024, enabling full human genome sequencing for a breakthrough price of just $100.

Market Challenge

The complex and frequently inconsistent reimbursement landscape constitutes a formidable barrier to the growth of the Global Genomic Medicine Market. Insurers and public payers often lack unified frameworks for evaluating the clinical and economic utility of advanced genomic assays, leading to unpredictable coverage decisions and frequent claim denials. This volatility creates significant financial risks for healthcare providers, who are hesitant to adopt comprehensive testing protocols if payment is not guaranteed. Consequently, the economic burden often shifts to patients, restricting access to personalized therapies and stifling the transition of genomic medicine from niche applications to standard clinical practice.

This fragmented coverage environment directly hampers market expansion by creating geographic disparities in accessibility. According to the American Cancer Society Cancer Action Network, in 2024, legislation requiring state-regulated insurance plans to cover comprehensive biomarker testing had been enacted in only 16 U.S. states. This statistic underscores the lack of a cohesive reimbursement strategy, as access to essential genomic profiling largely depends on a patient's location rather than medical necessity. Such regulatory patchworks complicate commercialization strategies for diagnostic developers and limit test volumes, thereby slowing the overall revenue growth of the genomic medicine sector.

Market Trends

The clinical translation of CRISPR and next-generation gene editing therapies is shifting the market from symptomatic management to curative interventions. This trend involves the progression of editing technologies to regulatory approvals, validating their commercial viability, while developers refine delivery mechanisms to broaden the addressable patient population beyond rare diseases. The financial impact is evident; according to CRISPR Therapeutics' 'Fourth Quarter and Full Year 2023 Financial Results' released in February 2024, the company reported a net income of $89.3 million, driven by milestone payments for the first approved CRISPR-based therapy. This profitability signals that gene editing is evolving into a sustainable revenue generator.

The proliferation of liquid biopsy for non-invasive cancer detection is redefining diagnostic standards by enabling early disease interception via blood-based testing. This approach minimizes procedural risks associated with tissue biopsies while facilitating real-time monitoring of tumor evolution. The market is witnessing increased adoption of these assays for therapy selection, supported by accumulating clinical validity data. This utilization is reflected in financial performance; according to Guardant Health's 'Second Quarter 2024 Financial Results' in August 2024, the company reported revenue of $177.2 million, a 29% increase compared to the prior year. Such growth underscores the expanding role of circulating tumor DNA analysis in routine oncology.

Key Market Players

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • BGI Genomics Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Invitae Corporation
  • PerkinElmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Oxford Nanopore Technologies

Report Scope

In this report, the Global Genomic Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Medicine Market, By Application

  • Oncology
  • Cardiology
  • Endocrinology
  • Rare Genetic Disorders
  • Others

Genomic Medicine Market, By End User

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others

Genomic Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genomic Medicine Market.

Available Customizations:

Global Genomic Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Oncology, Cardiology, Endocrinology, Rare Genetic Disorders, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Genomic Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genomic Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Genomic Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Genomic Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End User

7. Europe Genomic Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genomic Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End User
    • 7.3.2. France Genomic Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Genomic Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Genomic Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Genomic Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End User

8. Asia Pacific Genomic Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genomic Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End User
    • 8.3.2. India Genomic Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Genomic Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Genomic Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Genomic Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End User

9. Middle East & Africa Genomic Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genomic Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Genomic Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Genomic Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End User

10. South America Genomic Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genomic Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Genomic Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Genomic Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genomic Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Illumina, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. BGI Genomics Co., Ltd.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. QIAGEN N.V.
  • 15.6. Agilent Technologies, Inc.
  • 15.7. Invitae Corporation
  • 15.8. PerkinElmer, Inc.
  • 15.9. Pacific Biosciences of California, Inc.
  • 15.10. Oxford Nanopore Technologies

16. Strategic Recommendations

17. About Us & Disclaimer